Other CSC markers targeted by CAR-based ACT include the type II transmembrane receptor NKG2D, the interleukin three receptor alpha CD123 molecule and the disialoganglioside (GD2), all employed to develop CAR-T cells against both differentiated and CSCs, in GBM, AML and BC, respectively [140]. The gene discussed is KLRK1; the disease is glioblastoma.